Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Celso Acevedo

Clinical Cardiac Electrophysiology Ocala, FL Medical Doctor

NPI 1851390017 CMS profile 174525

2111 Sw 20Th Pl, Ocala, FL 34471

Open in the dashboard

General payments

$139,228

639 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,333 paid to institutions, not to them · program year 2019

Through program year 2025, Celso Acevedo of Ocala, FL is reported in the CMS Open Payments database as having received $139,228 across 639 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,333 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,402 120
2024 General $12,085 177
2023 General $22,921 110
2022 General $38,452 83
2021 General $20,594 59
2020 General $21,514 43
2019 General $10,260 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Celso Acevedo
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Celso Acevedo were reported at $13,402. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Celso Acevedo Clinical Cardiac Electrophysiology median Middle half National median
2019 $10,260 $2,361 $585–$8,260 $163
2020 $21,514 $993 $247–$4,351 $114
2021 $20,594 $1,185 $326–$4,739 $132
2022 $38,452 $2,073 $554–$6,789 $149
2023 $22,921 $2,568 $759–$8,159 $160
2024 $12,085 $2,557 $703–$7,403 $164
2025 $13,402 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $78,866 106 payments
  2. Impulse Dynamics (USA) Inc. $15,127 42 payments
  3. Integer Holdings Corporation $14,170 14 payments
  4. CardioFocus, Inc. $9,858 39 payments
  5. Abbott Laboratories $5,180 77 payments
  6. Boston Scientific Corporation $4,325 68 payments
  7. Biosense Webster, Inc. $3,852 145 payments
  8. AltaThera Pharmaceuticals LLC $2,089 3 payments
  9. Medtronic, Inc. $1,043 16 payments
  10. Cardiva Medical, Inc. $1,029 19 payments
  11. Other $3,690 110 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $68,250 50 payments
  2. Food and Beverage $22,228 522 payments
  3. Consulting Fee $20,333 17 payments
  4. Travel and Lodging $14,917 37 payments
  5. Honoraria $13,450 9 payments
  6. Education $51 4 payments
Products named General payments · program years 2019–2025
  1. LifeVest $78,866 106 payments
  2. Optimizer Cardiovascular $7,619 15 payments
  3. Optimizer Cardiovascular $7,085 10 payments
  4. OPTIMIZER Cardiovascular Device $6,830 17 payments
  5. OPTIMIZER Cardiovascular Device $6,830 17 payments
  6. HeartLight System Atrial Fibrilation $5,425 15 payments
  7. BIS/BIS Lead Adaptors & Extensions Unipolar and Bifurcated Lead Adaptors Destino Reach/Guidestar Steerable Sheath $5,200 1 payment
  8. Carto 3 $3,418 132 payments
  9. Destino Twist $2,860 1 payment
  10. Heartlight System Atrial Fibrillation $2,411 12 payments
  11. Other $24,845 338 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

920

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$125,222

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

53.2%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 74 $72,346
Multaq Dronedarone Hcl Brand 26 $25,870
Diltiazem 12hr Er Diltiazem Hcl Brand 23 $6,758
Flecainide Acetate Generic 123 $5,185
Sotalol Sotalol Hcl Brand 250 $4,847
Ranolazine Er Ranolazine Brand 30 $2,637
Diltiazem Hcl Generic 114 $2,195
Mexiletine Hcl Generic 20 $1,930
Amiodarone Hcl Generic 75 $1,303
Clopidogrel Clopidogrel Bisulfate Brand 86 $853

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$268,509

Medicare's payments for the services billed

Medicare patients

586

Average age 76

Services billed

1,503

267 women, 319 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 75%
Ischemic heart disease 71%
Arthritis 50%
Heart failure 49%
Diabetes 36%
Chronic kidney disease 35%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $151
  • PFIZER INC. $63
$214 74 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $66
$66 — —
NURTEC ODT
  • PFIZER INC. $61
$61 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $32
$32 — —
PAXLOVID
  • PFIZER INC. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

639 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record